Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tscan Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TCRX
Nasdaq
8731
https://www.tscan.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tscan Therapeutics Inc
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
- Jun 6th, 2023 11:00 am
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
- Jun 1st, 2023 8:10 pm
TScan Therapeutics Announces Closing of Public Offering
- Jun 1st, 2023 8:05 pm
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
- Jun 1st, 2023 11:00 am
TScan Therapeutics Announces Pricing of $140 Million Public Offering
- May 26th, 2023 4:37 am
TScan Therapeutics Announces Launch of Proposed Public Offering
- May 25th, 2023 8:06 pm
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
- May 24th, 2023 8:13 pm
TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients
- May 17th, 2023 8:35 pm
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
- May 17th, 2023 11:00 am
Institutional investors control 30% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 112%
- May 11th, 2023 11:33 am
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
- May 10th, 2023 12:15 pm
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- May 10th, 2023 11:00 am
Why Are TScan Therapeutics Shares Are Shooting Higher Today
- May 9th, 2023 5:29 pm
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
- May 9th, 2023 1:00 pm
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
- May 2nd, 2023 8:42 pm
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
- Apr 10th, 2023 11:00 am
TScan Therapeutics Announces CEO Transition
- Mar 31st, 2023 12:00 pm
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
- Mar 14th, 2023 11:00 am
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
- Mar 13th, 2023 8:05 pm
Scroll